SCHEMBL6073468

SCHEMBL6073468

CC(C)C[C@@H](CO)NC(=O)Nc1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 14/20 0.49
CCND1 P24385 12/20 0.49
CDK2 P24941 9/20 0.49
CCNA2 P20248 7/20 0.49
CDK1 P06493 4/20 0.46
CCNB1 P14635 4/20 0.46
CCNE1 P24864 3/20 0.46
CCND3 P30281 4/20 0.43
CCND2 P30279 3/20 0.43
CCNT1 O60563 1/20 0.42
CDK7 P50613 1/20 0.42
CDK9 P50750 1/20 0.42
CCNH P51946 1/20 0.42
STK17A Q9UEE5 2/20 0.42
FGFR1 P11362 4/20 0.42
FGFR2 P21802 4/20 0.42
FGFR4 P22455 4/20 0.42
FGFR3 P22607 4/20 0.42
SYK P43405 1/20 0.42
CCNE2 O96020 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6073563 0.89 CDK4 (0.50) CDK4CCND1CDK2CCNA2CDK1
SCHEMBL6074527 0.88 CDK4 (0.55) CDK4CCND1CDK2CCNA2CDK1
SCHEMBL6074119 0.86 CDK2 (0.48) CDK4CCND1CDK2CCNA2CDK1
SCHEMBL6073848 0.84 CDK4 (0.47) CDK4CCND1CDK2CCNA2CDK1
SCHEMBL6073488 0.83 CDK4 (0.50) CDK4CCND1CDK2CCNA2CDK1
SCHEMBL6074149 0.82 CDK4 (0.46) CDK4CCND1CDK2CCNA2CDK1
SCHEMBL7546855 0.82 CDK4 (0.50) CDK4CCND1CDK2CCNA2CDK1
SCHEMBL6074268 0.82 CDK4 (0.47) CDK4CCND1CDK2CCNA2CDK1
SCHEMBL6074273 0.82 CDK4 (0.54) CDK4CCND1CDK2CCNA2CDK1
SCHEMBL6073486 0.81 CDK4 (0.50) CDK4CCND1CDK2CCNA2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US claimed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US claimed
EP-1254137-A1 PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-11-06 EP claimed
WO-2001055147-A1 PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-08-02 WO claimed
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US disclosed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors CDK9, CDK19, CDK3 CDK4 19/4885CCND1 79/4885CDK2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.